Lilly-Boehringer Partnered Jardiance Slows Kidney Disease Progression
- Boehringer Ingelheim and Eli Lilly And Co said their diabetes drug Jardiance showed to slow the progression of chronic kidney disease.
- The companies said the EMPA-KIDNEY phase 3 trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for chronic kidney disease.
- In March, the trial was stopped early because an independent monitoring panel found the drug's benefit to be sufficiently clear.
- When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo.
- The results were announced today during the American Society of Nephrology (ASN)'s Kidney Week 2022.
- EMPA-KIDNEY trial also demonstrated a significant reduction in all-cause hospitalizations (14%) vs. placebo, one of the pre-specified key secondary confirmatory endpoints.
- The overall safety data was generally consistent with previous findings, confirming the well-established safety profile of Jardiance.
- Reductions in other key secondary endpoints of hospitalization for heart failure, cardiovascular death, or all-cause death were not statistically significant. However, the power to detect this was limited by the number of events observed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.